Intestinal gas bubbles and gas–liquid interfaces

Intestinal gas bubbles and the gas–liquid interfaces within the gastrointestinal tract represent a physical therapeutic target for antifoaming agents. Gas in the gut can become trapped in small, mucus-coated bubbles, leading to symptoms like bloating, distension, and abdominal pain (StatPearls, 2023). Drugs like simethicone act directly on these interfaces by lowering surface tension, which allows smaller bubbles to coalesce into larger ones that are more easily eliminated via belching or flatulence (PubChem, CID 6433516). This target is unique because it involves a physical-chemical interaction rather than binding to a protein or receptor. It is clinically relevant in treating functional gastrointestinal disorders and improving visibility during diagnostic procedures like endoscopy and radiography (NIH, 2022). Because the target is physical rather than biological, the therapeutic effect is localized and does not involve systemic absorption of the drug (Mayo Clinic, 2023).

Other names

Gastrointestinal gas bubblesIntestinal gas-liquid interfaceIntestinal foamGI gas bubbles

Simethicone acts as an antifoaming agent by decreasing the surface tension of gas bubbles in the gastrointestinal tract. This physical action causes the bubbles to break or coalesce into larger bubbles, which have a smaller total surface area and are more easily passed through the digestive system via belching or flatulence (StatPearls, 2023; PubChem, CID 6433516).